ClinicalTrials.gg
RecruitingNCT06363994Updated Dec 27, 2024

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

A Phase 3 interventional study of Orelabrutinib and Bendamustine Injection in Mantle Cell Lymphoma, sponsored by InnoCare Pharma Inc.. Recruiting at 39 sites in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by InnoCare Pharma Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
476
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell — 8 open to participants now, 8 under way, 2 of them phase 3. orelabrutinib · Lymphoma, Mantle-Cell.

Planned enrollment
Largest of 10
476 · median 42
Started
2024
with 2 others
Phase 3
3 of 10
2 open now
Registered
3rd of 10
by date
Lead sponsor
1 of 10
InnoCare Pharma Inc.

Among the 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell, this one has the largest planned enrollment, is one of 3 that started in 2024, is one of 3 in phase 3, and was the 3rd registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

8 of the 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL)

03

Conditions studied

  • Mantle Cell Lymphoma
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects ≥ 65 of age, or ≥ 60 and \< 65 years old who are ineligible for stem cell transplant or have refused stem cell transplantation due to reason(s) including: Have not received prior systemic therapies for MCL.
  2. Modified Ann Arbor stage II-IV. Patients with stage II require systemic treatment to be eligible, at the discretion of the investigator.
  3. Histopathological confirmed MCL, expression of Cyclin D1 and/or t (11; 14) chromosomal translocation. Either fresh tissue or FFPE for diagnosis must be sent to central lab for final confirmation after randomization.
  4. At least one measurable site of disease (the longest axis of the lymph node lesion is > 1.5 cm, or the longest diameter of the extranodal lesion is > 1.0 cm).
  5. PS score of 0 to 2.

Exclusion criteria

Exclusion Criteria:

  1. Existing or prior history of other malignant tumor and no evidence of recurrence and within 2 years before screening.
  2. Subjects with evident gastrointestinal dysfunction that may affect drug intake, transport or absorption, or subjects who have undergone total gastrectomy.
  3. Subjects for whom the goal of therapy is tumor debulking prior to stem cell transplant.
  4. Use of strong inhibitors or strong inducers of cytochrome P450 3A within 14 days or 5 half-lives, whichever is longer, before the first dose of study treatment; or plan to use strong inhibitors or strong inducers of during the study.
  5. Known central nervous system lymphoma.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
476 participants (estimated)

Study arms

  • Active comparator
    Arm A

    Drug: Orelabrutinib · Drug: Bendamustine Injection · Drug: Rituximab

  • Active comparator
    Arm B

    Drug: Bendamustine Injection · Drug: Rituximab · Drug: Orelabrutinib Placebo

Interventions

  • Eligible patients will receive Orelabrutinib orally as per the protocol,until disease progression or other reasons for treatment discontinuation,whichever comes first.

  • Eligible patients will receive Bendamustine by injection as per the protocol

  • Eligible patients will receive Rituximab by injection as per the protocol

  • DrugOrelabrutinib Placebo

    Eligible patients will receive Orelabrutinib Placebo orally as per the protocol

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Time frame: 28 days

  2. Progression-free Survival (PFS) for Arm A vs. Arm B

    Time frame: Approximately 7 years

07

Study locations

19 of 39 sites recruiting
  • Beijing Cancer Hospital
    Beijing, China
    Recruiting
    • Yuqin Song · Contact
  • Peking University Third Hospital
    Beijing, China
    Recruiting
    • Hongmei Jing · Contact
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, China
    Recruiting
    • Yanli Yang · Contact
  • First Hospital of Jilin University
    Changchun, China
    Not yet recruiting
    • Ou Bai · Contact
  • Hunan Cancer Hospital
    Changsha, China
    Recruiting
    • Hui Zhou · Contact
  • The First People's Hospital of Changzhou
    Changzhou, China
    Not yet recruiting
    • Weiying Gu · Contact
  • Sichuan Provincial People's Hospital
    Chengdu, China
    Recruiting
    • Xiaobing Huang · Contact
  • West China Hospital of Sichuan University
    Chengdu, China
    Not yet recruiting
    • Liqun Zhou · Contact
  • Chongqinq Cancer Hospital
    Chongqing, China
    Recruiting
    • Yingyu Nan · Contact
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, China
    Not yet recruiting
    • Xiaoqiong Tang · Contact
  • The second Hospital of Dalian Medical University
    Dalian, China
    Not yet recruiting
    • Xiuhua Sun · Contact
  • Fujing Cancer Hospital
    Fuzhou, China
    Recruiting
    • Hongming He · Contact
  • Union Hospital Affiliated to Fujian Medical University
    Fuzhou, China
    Not yet recruiting
    • Tingbo Liu · Contact
  • Guangdong Provincial People's Hospital
    Guangzhou, China
    Recruiting
    • Wenyu Li · Contact
  • Sun Yat-sen University Cancer Center
    Guangzhou, China
    Recruiting
    • Zhiming Li · Contact
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, China
    Not yet recruiting
    • Wenbin Qian · Contact
  • Zhejiang University Medical School affiliated to the first Hospital
    Hangzhou, China
    Recruiting
    • Wenjuan Yu · Contact
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, China
    Recruiting
    • Jian Ge · Contact
  • Shandong Provincial Hospital
    Jinan,, China
    Not yet recruiting
    • Xiaosheng Fang · Contact
  • Cancer Hospital of Shandong First Medical University
    Jinan, China
    Not yet recruiting
    • Zengjun Li · Contact
  • The First Affiliated Hospital of Ningbo University
    Jinan, China
    Recruiting
    • Guifang Ouyang · Contact
  • The First Affiliated Hospital of Henan University of Science & Technology
    Luoyang, China
    Not yet recruiting
    • Ling Qin · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, China
    Recruiting
    • Fei Li · Contact
  • Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University
    Nanjing, China
    Not yet recruiting
    • Jingyan Xu · Contact
  • Cancer Hospital Affiliated to Fudan University
    Shanghai, China
    Not yet recruiting
    • Qunling Zhang · Contact
  • Huashan Hospital of Fudan University
    Shanghai, China
    Recruiting
    • Yan Yuan · Contact
  • Shengjing Hospital of China Medical University
    Shenyang, China
    Not yet recruiting
    • Aijun Liao · Contact
  • The First Affiliated Hospital of China Medical University
    Shenyang, China
    Recruiting
    • Xiaojing Yan · Contact
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, China
    Not yet recruiting
    • Lihong Liu · Contact
  • Shanxi Cancer Hospital
    Taiyuan, China
    Not yet recruiting
    • Liping Su · Contact
  • Tianjin Cancer Hospital
    Tianjin, China
    Recruiting
    • Zhengzi Qian · Contact
  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and
    Wuhan, China
    Recruiting
    • Liling Zhang · Contact
  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and
    Wuhan, China
    Not yet recruiting
    • Jia Kui · Contact
  • The Tumor Hospital Affiliated to Xinjiang Medical University
    Wulumuqi, China
    Recruiting
    • Shujuan Wen · Contact
  • The First Affiliated Hospital of the PLA Air Force Military Medical University (Xijing Hospital)
    Xi'an, China
    Not yet recruiting
    • Guangxun Gao · Contact
  • The Second Affiliated Hospital Of Xi'an Jiaotong University
    Xi'an, China
    Not yet recruiting
    • Wanhong Zhao · Contact
  • Yibin Second People's Hospital
    Yibin, China
    Not yet recruiting
    • Shihua Huang · Contact
  • Henan Cancer Hospital
    Zhengzhou, China
    Recruiting
    • Keshu Zhou · Contact
  • Henan Provincial People's Hospital
    Zhengzhou, China
    Not yet recruiting
    • Zunmin Zhu · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jun 2031, 84 months after the start.

Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's planned 84 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2024
First posted
Apr 12, 2024
StartActual
May 29, 2024
Primary completionEst.
Jun 25, 2031
CompletionEst.
Jun 25, 2032
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06363994
Responsible party
Sponsor
First posted
Apr 12, 2024
Start date
May 29, 2024
Primary completion
Jun 25, 2031 (estimated)
Completion
Jun 25, 2032 (estimated)
Last update
Dec 27, 2024

Study contacts

Alexia Lu
Contact
CO_HGRAC@innocarepharma.com
010-66609745

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion